New Patent for Annovis Bio's Buntanetap Expands Treatment Scope for Brain Infections Through 2044
ANVS has more than doubled off its 52-week low of $1.11.
Summary
Annovis Bio has secured a U.S. patent for its lead drug candidate, buntanetap, covering its use in preventing and treating neurological injuries caused by brain infections. This patent extends intellectual property protection for buntanetap through 2044 and expands its potential therapeutic applications beyond Alzheimer's and Parkinson's disease, adding value to the company's core asset. This positive IP development provides a much-needed counterpoint amidst recent negative news, including the CFO's departure and the company's 10-K highlighting substantial doubt about its ability to continue as a going concern and a NYSE delisting notice. Investors will continue to monitor the company's financial stability, progress in its Phase 3 clinical trials for AD/PD, and any further developments regarding its NYSE listing.
At the time of this announcement, ANVS was trading at $2.27 on NYSE in the Life Sciences sector, with a market capitalization of approximately $60.1M. The 52-week trading range was $1.11 to $5.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.